



## **BEAT BioTherapeutics Corporation**

### **BEAT BioTherapeutics Corporation appoints Michael Kranda as CEO**

(SEATTLE) April 8, 2013 - BEATBio announced today the appointment of Michael Kranda as CEO and Director. BEATBio is a Seattle, WA based biotechnology company focused on the development of a novel gene therapy to improve cardiac performance in the setting of heart failure. A seasoned biotech executive, Kranda brings years of industry operating and corporate development experience to BEATBio. He was formerly a Managing Director at Vulcan Capital, heading up their biotechnology and life science investments. Prior roles include CEO of Oxford GlycoSciences, where he established the company as a world leader in Proteomics and President, Chief Operating Officer and Director at Immunex.

"Michael's experience in biotech company development, operations, manufacturing and finance are a great addition to BEATBio as we move our promising portfolio of technologies into development," said Gregory Mahairas, Ph.D., Chief Scientific Officer and director of BEATBio. "Mr. Kranda is a proven leader with extensive biotechnology experience and will be leading an outstanding team at BEATBio," said Dr. Charles Murry, Director of the University of Washington's Center for Cardiovascular Biology and Co-director of the Institute for Stem Cell Regenerative Medicine (ISCRM).

"I'm pleased to join BEATBio and look forward to working with the founders and the University of Washington to help build an important gene therapy company with the potential to address serious unmet medical needs in cardiovascular disease," said Kranda.

About BEATBio: BEATBio is a Seattle, WA based biotechnology company focused on the development of a novel gene therapy for heart failure. . BEATBio's technologies were developed by a founding scientific team including Dr. Charles Murry, Director of the University of Washington's Center for Cardiovascular Biology, Michael Regnier, Ph.D., Vice-Chairman of the Department of Bioengineering at the University of Washington, Buddy Ratner, Ph.D, Director of UW Engineered Biomaterials and Michael Laflamme, MD, PH.D., UW Professor of Pathology & Cardiovascular Biology. BEATBio holds an exclusive, worldwide license from the University of Washington to a suite of technologies and associated intellectual property for cardiovascular medicine, including gene and cell therapy, bioengineered materials and biological pace-makers. Initial funding for BEATBio was provided by the Hope Heart Institute.

For more information please visit [www.beatbiotherapeutics.com](http://www.beatbiotherapeutics.com) or contact:

Michael Kranda, CEO  
mkranda@BEATBiotherapeutics.com  
(M) 425-647-4236

Gregory Mahairas Ph.D., President & CSO  
gmahairas@BEATBiotherapeutics.com  
(M) 206 295-7905